Johnson & Johnson is reassuring investors that its pharmaceutical business will grow through the loss of exclusivity (LOE) of Stelara (ustekinumab), anticipated in the second half of 2023. While the diversified health care company generated steady growth in the third quarter, despite currency and inflation headwinds, persistent macroeconomic challenges coupled with the big upcoming patent exclusivity loss will create difficult business conditions for J&J to navigate next year.
Nonetheless, management told the firm’s third quarter sales and earnings call on 18 October that it is prepared to rise to the challenge and reaffirmed its